

Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor -Pipeline Insight, 2020

<https://marketpublishers.com/r/P662EF934B1EN.html>

Date: June 2020

Pages: 120

Price: US\$ 1,500.00 (Single User License)

ID: P662EF934B1EN

Abstracts

This report can be delivered to the clients within 48 hours

OVERVIEW

'Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor - Pipeline Insight, 2020' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor pipeline landscape is provided, which includes the topic overview and Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor mechanism of action. The assessment part of the report embraces, in-depth Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor pipeline development activities

The report provides insights into:

All the companies developing therapies of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor with aggregate therapies developed by each company for the same.

Different therapeutic candidates in early-stage, mid-stage and late stage of development for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor.

Key players involved in Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

Collaborations (company-company collaborations and company-academia collaborations), licensing agreements and financing details for future developments of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.

Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Analytical Perspective by DelveInsight

In-depth Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Commercial Assessment of products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, acquisition deal value trends. The sub-segmentation is described in the report, which provides company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form.

Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this mechanism of action.

SCOPE OF THE REPORT

The Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA the complete product development cycle, including all clinical and nonclinical stages.

It comprises of detailed profiles of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor therapeutic products with key coverage of involved technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

Elucidated Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor research and development progress and trial details, results wherever available, are also included in the pipeline study.

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor.

REPORT HIGHLIGHTS

In the coming years, the Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor market is set to change due to the extensive research in this field, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics are working to assess challenges and seek opportunities that could influence Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

There are several companies involved in developing therapies for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor. Launch of emerging therapies of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor will significantly impact the market.

A better understanding of the target mechanism will also contribute to the development of novel therapeutics for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor.

Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

KEY QUESTIONS

What are the current treatment options available based on the Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor?

How many companies are developing therapies by working on Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor?

What are the principal therapies developed by these companies in the industry?

How many therapies are developed by each company for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor to treat disease condition?

How many emerging therapies are in early-stage, mid-stage, and late stage of development for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor?

Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor therapies?

Which are the dormant and discontinued products and the reasons for the same?

What is the unmet need for current therapies developed based on this

mechanism of action?

What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor and their status?

What are the results of the clinical studies and their safety and efficacy?

What are the key designations that have been granted for the emerging therapies for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor?

How many patents are granted and pending for the emerging therapies of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor?

Contents

1. REPORT INTRODUCTION

2. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR

- 2.1. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Overview
- 2.2. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Classification
- 2.3. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Structure
- 2.4. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Mechanism of Action
- 2.5. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Application

3. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 3.1. In-depth Commercial Assessment
 - 3.1.1. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends
 - 3.1.1.1. Assessment Summary
 - 3.1.2. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Collaboration Deals
 - 3.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
 - 3.1.2.2. Company-University Collaborations (Licensing/Partnering) Analysis
 - 3.1.2.3. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Acquisition Analysis

4. THERAPEUTIC ASSESSMENT

- 4.1. Clinical Assessment of Pipeline Drugs
 - 4.1.1. Assessment by Phase of Development
 - 4.1.2. Assessment by Product Type (Mono/Combination)
 - 4.1.2.1. Assessment by Stage and Product Type
 - 4.1.3. Assessment by Route of Administration
 - 4.1.3.1. Assessment by Stage and Route of Administration
 - 4.1.4. Assessment by Molecule Type
 - 4.1.4.1. Assessment by Stage and Molecule Type
 - 4.1.5. Assessment by MOA
 - 4.1.5.1. Assessment by Stage and MOA
 - 4.1.6. Assessment by Target
 - 4.1.6.1. Assessment by Stage and Target

5. LATE STAGE PRODUCTS (PHASE-III)**6. MID STAGE PRODUCTS (PHASE-II)****7. EARLY STAGE PRODUCTS (PHASE-I)****8. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS****9. INACTIVE PRODUCTS****10. DORMANT PRODUCTS****11. DISCONTINUED PRODUCTS****12. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR PRODUCT PROFILES**

12.1. Drug Name: Company

12.1.1. Product Description

12.1.1.1. Product Overview

12.1.1.2. Mechanism of action

12.1.2. Research and Development

12.1.2.1. Clinical Studies

12.1.3. Product Development Activities

12.1.3.1. Collaboration

12.1.3.2. Agreements

12.1.3.3. Acquisition

12.1.3.4. Patent Detail

12.1.4. Tabulated Product Summary

12.1.4.1. General Description Table

Detailed information in the report

13. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR KEY COMPANIES**14. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR KEY PRODUCTS****15. DORMANT AND DISCONTINUED PRODUCTS**

15.1. Dormant Products

- 15.1.1. Reasons for being dormant
- 15.2. Discontinued Products
 - 15.2.1. Reasons for the discontinuation

16. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR - UNMET NEEDS

17. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR - FUTURE PERSPECTIVES

18. POLY (ADP-RIBOSE) POLYMERASE 1 (PARP) INHIBITOR ANALYST REVIEW

19. APPENDIX

20. REPORT METHODOLOGY

- 20.1. Secondary Research
- 20.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1 : Assessment Summary
- Table 2 : Company-Company Collaborations (Licensing/Partnering) Analysis
- Table 3 : Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Acquisition Analysis
- Table 4 : Assessment by Phase of Development
- Table 5 : Assessment by Product Type (Mono/Combination)
- Table 6 : Assessment by Stage and Product Type
- Table 7 : Assessment by Route of Administration
- Table 8 : Assessment by Stage and Route of Administration
- Table 9 : Assessment by Molecule Type
- Table 10 : Assessment by Stage and Molecule Type
- Table 11 : Assessment by MOA
- Table 12 : Assessment by Stage and MOA
- Table 13 : Assessment by Target
- Table 14 : Assessment by Stage and Target
- Table 15 : Late Stage Products (Phase-III)
- Table 16 : Mid Stage Products (Phase-II)
- Table 17 : Early Stage Products (Phase-I)
- Table 18 : Pre-clinical and Discovery Stage Products
- Table 19 : Inactive Products
- Table 20 : Dormant Products
- Table 21 : Discontinued Products

List Of Figures

LIST OF FIGURES

Figure 1 : Structure

Figure 2 : Mechanism

Figure 3 : Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends

Figure 4 : Company-Company Collaborations (Licensing/Partnering) Analysis

Figure 5 : Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Acquisition Analysis

Figure 6 : Assessment by Phase of Development

Figure 7 : Assessment by Product Type (Mono/Combination)

Figure 8 : Assessment by Stage and Product Type

Figure 9 : Assessment by Route of Administration

Figure 10 : Assessment by Stage and Route of Administration

Figure 11 : Assessment by Molecule Type

Figure 12 : Assessment by Stage and Molecule Type

Figure 13 : Assessment by MOA

Figure 14 : Assessment by Stage and MOA

Figure 15 : Late Stage Products (Phase-III)

Figure 16 : Mid Stage Products (Phase-II)

Figure 17 : Early Stage Products (Phase-I)

Figure 18 : Pre-clinical and Discovery Stage Products

Figure 19 : Inactive Products

Figure 20 : Dormant Products

Figure 21 : Discontinued Products

Figure 22 : Unmet Needs

KEY COMPANIES

Abbvie

Pfizer

Esai

Esai

Esai

Mitsubishi Tanabe Pharma Corporation

AbbVie

Jiangxi Qingfeng Pharmaceutical

Zydus Cadila

Jeil Pharmaceutical
Jeil Pharmaceutical
Angion Biomedica
Sanofi
NewGen Therapeutics
Kanion
& list continues

I would like to order

Product name: Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor -Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/P662EF934B1EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P662EF934B1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970